Substituting Medical Cannabis for Medications Among Patients with Rheumatic Conditions in the United States and Canada
Although the determination of causality is limited by our cross-sectional design, these findings suggest that an appreciable number of people with rheumatic diseases substitute medications with MC for symptom management. Inhalation of MC products containing some THC was most commonly identified among those substituting, and disease characteristics did not differ by substitution status. Further study is needed to better understand the role of MC for symptom management in rheumatic conditions.
Authors
- Daniel J. Kruger (ORCID: https://orcid.org/0000-0002-2757-7016)
- Kevin F. Boehnke (ORCID: https://orcid.org/0000-0003-3696-3979)
- David A. Williams (ORCID: https://orcid.org/0000-0002-5052-4895)
- J. Ryan Scott (ORCID: https://orcid.org/0000-0002-4900-0891)
- Mary‐Ann Fitzcharles (ORCID: https://orcid.org/0000-0002-1091-3175)
- Tristin Smith (ORCID: https://orcid.org/0000-0002-0338-5618)
- Rachel S. Bergmans (ORCID: https://orcid.org/0000-0001-5740-6691)
- Marc O. Martel (ORCID: https://orcid.org/0000-0002-8143-4622)
Institutions
- University of Michigan (US)
- McGill University (CA)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1002/acr2.11717
- Citations
- 3
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.34
Funders
- National Institutes of Health
- National Institute on Drug Abuse